Sarah L. Pass
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Protein Kinase Regulation and GTPase Signaling, Growth Hormone and Insulin-like Growth Factors, Crystallography and molecular interactions, Receptor Mechanisms and Signaling
Most-Cited Works
- → Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014(2013)204 cited
- → Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R)(2016)31 cited
- → Discovery of AZD3147: A Potent, Selective Dual Inhibitor of mTORC1 and mTORC2(2015)28 cited
- → Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours(2014)19 cited
- → Abstract 917: AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer(2012)17 cited
- → CCDC 1019570: Experimental Crystal Structure Determination(2015)
- → IGFR-1R complex with a pyrimidine inhibitor.(2016)